Skip to main content

Mintz IRA Update — Fifth Edition: Q3 2025

Mintz’s Managed Care, PBMs & Pharmacies Practice is pleased to present the ‘Fifth Edition: Q3 2025’ of our Mintz IRA Update, a regular publication that delves into developments of the Inflation Reduction Act of 2022 (IRA) and their impact on pharmaceutical supply chain stakeholders.

To help our clients track and stay up to date with the developments related to the IRA, the Mintz IRA Update provides informed and insightful analyses on the issues that directly affect your business.

We also note that given the IRA’s importance, we offer clients personalized, one-on-one information sessions regarding the short- and long-term impacts of the IRA. If you are interested, please contact Theresa Carnegie, Tara Dwyer, Rachel Alexander, or Lauren Moldawer for more information (contact details included further below).

We hope you find the Mintz IRA Update to be a useful resource. If you have any recommendations on additional content that would be helpful to see in future editions, please do not hesitate to reach out to our team to let us know.

We hope you enjoy, and please subscribe to receive future editions!

Theresa C. Carnegie, Tara E. Dwyer, Rachel A. Alexander, & Lauren M. Moldawer

mintz ira update 07-2024

Podcast Companion Piece

For a quick listen of the top hits in the report, be sure to check out our 5-minute podcast here.


 

IRA Medicare Drug Price Negotiation Program Updates for Q3 2025

A discussion of key takeaways from CMS’s most recent draft guidance for the third cycle of the Negotiation Program and how recent legislative efforts may curb the rollout and effects of the Negotiation Program.

 

Still Undefeated: Government Notches Three More Victories in Negotiation Program Lawsuits

A comprehensive update on the government’s continued success in defending the Negotiation Program, highlighting recent court rulings that have largely favored the government’s position emphasizing the voluntary nature of Medicare participation.

 

Redesigning Part D for CY 2026

A breakdown of CMS’s recently finalized CY 2026 Part D Redesign Program Instructions, which build upon the IRA’s reforms to Part D in an effort to improve affordability and clarify coverage standards.

 

Under Pressure: The Trump Administration’s Drug Pricing Executive Orders

A review of recent unilateral actions taken by the Trump administration to address prescription drug costs, including two Executive Orders and direct outreach to pharmaceutical manufacturers.

 

340B Roundup

Since our last 340B update, there has been significant action in the 340B space. Read about the latest in the 340B space:

 

PhRMA’s 2025 Policy Agenda and the Industry’s Crossroads with the IRA and Drug Pricing Reform

PhRMA’s 2025 policy agenda outlines a strategic response to evolving US drug pricing reforms, emphasizing the protection of pharmaceutical innovation while advocating for regulatory changes across pricing, supply chain oversight, and access programs. The agenda reflects growing industry tensions with federal and state initiatives, particularly those introduced under the Inflation Reduction Act and related executive actions.

 

Disrupting the Pharmaceutical Supply Chain: The Era of the DTC Model

President Trump’s Executive Order on most-favored-nation drug pricing has accelerated pharmaceutical manufacturers’ adoption of direct-to-consumer (DTC) drug delivery models. This article examines emerging partnerships with telehealth platforms, regulatory scrutiny around fraud and advertising, and the potential disruptions this model poses for traditional drug distribution.

 

Medicare Part B Physician Fee Schedule Guidance and Its Potential Implications for Medicare Part D

This discussion of CMS’s CY 2026 Physician Fee Schedule Proposed Rule focuses on its new requirements for evaluating and reporting Bona Fide Service Fees in Medicare Part B, with potential implications for Part D.

 

The Uncertain State of Affairs for GLP-1s

A discussion of how GLP-1 drugs are transforming obesity treatment while raising urgent questions about affordability, access, regulatory scrutiny, and the long-term role of public policy in shaping their impact on the US health care system.

Authors

Rachel A. Alexander, a Member at Mintz, is a seasoned health law attorney and litigator who represents health plans, payors, and managed care entities in all aspects of managed care and payor regulatory, transactional, and litigation matters. She has a specialized focus on pharmacy benefit and drug pricing–related issues. She is regularly called on to help clients navigate pharmacy benefit manager (PBM) contract negotiation, administration, and procurement matters and provide guidance on compliance with federal law.
Theresa advises clients on all aspects of the pharmaceutical supply chain, including counseling industry stakeholders on a range of business, legal, transactional, and compliance matters. She provides clients with strategic counseling and creative business modeling that considers legal restrictions and regulatory risk in light of innovation and business goals.
Tara advises managed care organizations, pharmaceutical services providers such as PBMs, and integrated delivery systems, and companies that invest in them, on matters relating to compliance with federal health care program regulations, federal and state fraud, waste and abuse laws and plan benefits.
Lauren advises pharmacies, PBMs, managed care organizations, and other payors on transactional, regulatory, and fraud and abuse matters, drawing upon her experience working for the Federal Coordinated Health Care Office.
Stephnie advises clients across the health care industry on regulatory, transactional, and compliance matters.
Hassan Shaikh

Hassan Shaikh

Associate

Hassan advises a broad range of clients across the health care industry—including health care systems, pharmacies, and private equity firms investing in health care companies—in complex industry transactions and compliance and regulatory matters.
Mitchell focuses his practice on complex commercial litigation, antitrust matters, and class actions in federal and state courts.
Xavier represents clients in the health care and life sciences fields on health care regulatory and fraud and abuse matters. He also handles Medicare and Medicaid reimbursement issues in transactions and business arrangements.
Samantha Hawkins is an Associate at Mintz whose practice encompasses a broad range of complex transactions, compliance and regulatory issues, and governance matters for clients across the health care sector, with an emphasis on pharmacy benefit manager (PBM) contract negotiation.
Abdie Santiago is an Associate at Mintz who represents life sciences and health care companies in a broad spectrum of regulatory, fraud and abuse, and transactional matters. He assists clients with government drug pricing mandates, Medicare and Medicaid coverage requirements, Anti-Kickback Statute and False Claims Act investigations, and due diligence for health care practice transactions.
Rachel Yount is a Mintz attorney who focuses her practice on health care industry transactions. Her clients include hospitals, health systems and plans, physician organizations, and pharmacy benefit managers.
Jordyn Flaherty

Jordyn Flaherty

Jordyn Flaherty is a Mintz Project Analyst.